EUVIMEDEUVIMED entdecken
Übersichtsarbeit

From Gene to Hope: Rett Syndrome and the Rise of Molecular Therapies

Yoann Leblay iD, Marie-Solenne Felix iD, Jean-Christophe Roux iD, Nicolas Panayotis iD

Molecular Diagnosis & Therapy · 2026-07 · 30 (4) · 575-585

DOI: 10.1007/s40291-026-00847-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Diagnosis & Therapy, online erschienen am 13.04.2026. Verfasst von Yoann Leblay und 3 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, CNRS, Saints-Pères Paris Institute for the Neurosciences, 75006, Paris, France. Hauptthemen laut MEDLINE: Rett Syndrome, Genetic Therapy, Methyl-CpG-Binding Protein 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rett syndrome is a rare X-linked neurodevelopmental disorder caused by mutations in MECP2, a gene critical for neuronal function, chromatin organization, and synaptic plasticity. After a period of apparently normal early development, individuals with Rett syndrome experience rapid regression followed by lifelong neurological impairment. Notably, preclinical studies have shown that restoration of MeCP2 expression can reverse established symptoms in adult mice, positioning Rett syndrome as a promising target for molecular therapies. However, MECP2 is extremely dosage sensitive and both insufficient and excessive expression are harmful, creating a narrow therapeutic window and a major challenge for treatment design. This review examines the evolving landscape of gene- and RNA-based therapies for Rett syndrome, with a focus on strategies that enable precise MeCP2 replacement, dosage control, and widespread central nervous system delivery. We discuss clinical-stage adeno-associated virus gene replacement programs, including TSHA-102 and NGN-401, highlighting their vector designs, regulatory elements, delivery approaches, and emerging clinical data. Advances in adeno-associated virus capsid engineering and vector optimization aimed at improving neuronal targeting while minimizing peripheral exposure and immune toxicity are also reviewed. Beyond gene supplementation, we explore approaches that restore endogenous MECP2 regulation, such as reactivation of the inactive X chromosome, as well as DNA and RNA editing strategies. Collectively, these advances reflect a shift toward precision-regulated therapies for Rett syndrome that may provide a model for treating other dosage-sensitive neurodevelopmental disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rett SyndromeGenetic TherapyMethyl-CpG-Binding Protein 2HumansAnimalsMutationGenetic VectorsDependovirusMolecular Targeted TherapyGene Therapy Agents

Substanzen

Methyl-CpG-Binding Protein 2MECP2 protein, human

Autor:innen und Institutionen

  • Université Paris Cité, CNRS, Saints-Pères Paris Institute for the Neurosciences, 75006, Paris, France.
  • Aix Marseille Univ, INSERM, MMG, U1251, Faculté de Médecine Timone, 13005, Marseille, France.
  • INMED, INSERM, Aix Marseille University, 13273, Marseille, France. jean-christophe.roux@univ-amu.fr.
  • Université Paris Cité, CNRS, Saints-Pères Paris Institute for the Neurosciences, 75006, Paris, France. nicolas.panayotis@u-paris.fr.

ORCID-Profile: Yoann Leblay, Marie-Solenne Felix, Jean-Christophe Roux, Nicolas Panayotis

Zitieren

APA

Leblay, Y., Felix, M. S., Roux, J. C., & Panayotis, N. (2026). From Gene to Hope: Rett Syndrome and the Rise of Molecular Therapies. Molecular Diagnosis & Therapy, 30(4), 575-585. https://doi.org/10.1007/s40291-026-00847-4

Vancouver

Leblay Y, Felix MS, Roux JC, Panayotis N. From Gene to Hope: Rett Syndrome and the Rise of Molecular Therapies. Molecular Diagnosis & Therapy. 2026;30(4):575-585. doi:10.1007/s40291-026-00847-4

BibTeX
@article{Leblay2026,
  author = {Leblay, Yoann and Felix, Marie-Solenne and Roux, Jean-Christophe and Panayotis, Nicolas},
  title = {From Gene to Hope: Rett Syndrome and the Rise of Molecular Therapies},
  journal = {Molecular Diagnosis & Therapy},
  year = {2026},
  volume = {30},
  number = {4},
  pages = {575--585},
  doi = {10.1007/s40291-026-00847-4}
}
Kostenlos starten →